GlassScriptPhysician profile
Teal L Vinger
NPI 1578148284
$5,424.28
in general payments reported to CMS, 2019-2025
24 companies · $1,048 in 2025
The $1,048 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $747 · 2022: $1,138 · 2023: $1,246 · 2024: $1,245 · 2025: $1,048.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,507 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,507.36 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,491.55 | 2021-2025 | Wegovy, Ozempic |
| Abbvie INC. | $1,460.15 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $985.52 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $405.66 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $223.49 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $218.00 | 2022 | |
| Glaxosmithkline, LLC. | $107.75 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Rhythm Pharmaceuticals, INC. | $78.65 | 2022-2025 | Imcivree, Imcivree |
| Otsuka America Pharmaceutical, INC. | $52.61 | 2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $47.67 | 2024-2025 | Caplyta |
| Merck Sharp & Dohme LLC | $41.76 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $39.72 | 2024 | Gvoke Hypopen |
| Alkermes, INC. | $39.47 | 2024-2025 | Lybalvi, Aristada |
| Clarus Therapeutics INC. | $34.21 | 2021 | |
| Antares Pharma, INC. | $24.63 | 2023 | Nocdurna, Xyosted, Tlando |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vivus LLC | $23.94 | 2022 | |
| Exact Sciences Corporation | $23.20 | 2025 | Cologuard Collection Kit |
| Ibsa Pharma INC. | $21.14 | 2025 | Tirosint, Flector, Licart |
| Halozyme INC | $19.03 | 2023 | |
| Tms Neurohealth Centers INC. | $18.33 | 2025 | Tms Neurohealth Centers INC. |
| Vanda Pharmaceuticals INC. | $18.27 | 2025 | Ponvory |
| Aimmune Therapeutics, INC. | $18.11 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $17.95 | 2021 | |
| Axsome Therapeutics, INC. | $13.47 | 2025 | Sunosi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Teal Vinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.